Methadone in Post-Herpetic Neuralgia Pain

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01752699

Acronym

NPH

Enrollment

Registered

2012-12-19

Start date

1998-01-31

Completion date

2013-03-31

Last updated

2013-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-herpetic Neuralgia

Keywords

neuropathic pain,, post-herpetic neuralgia,, methadone,

Brief summary

Neuropathic pain is a common condition and affecting 40 to 70% of the general population. Post-herpetic neuralgia is a condition almost complex and requires a multi modal treatment. Aim: This is a pilot proof-of-principle study designed to evaluate the use of low-dose methadone in post-herpetic neuralgia patients who remained refractory after first and second line treatment for post-herpetic neuralgia (PHN) and had indication for the association of an opioid agent to their current drug regimen.

Interventions

DRUGMethadone

patients with post-herpetic neuralgia take methadone or placebo to treat pain symptoms.

DRUGPlacebo

patients with post-herpetic neuralgia take placebo to treat the pain symptoms.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with chronic (\>6 months) symptomatic PHN * with visual analogical scale \>40/100mm * use of first and second line drugs (tricyclic antidepressants, venlafaxine and gabapentinoids)

Exclusion criteria

* Don't full the criteria above

Design outcomes

Primary

Measure	Time frame	Description
Change in baseline Pain	baseline (visit inclusion) and three moths latter	Assessing by verbal analog scale (VAS)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 23, 2026